Song Yao-Hua, Shao Lianbo, Zhang Yu, Zhou Jin, Liu Bin, Pan Xiangbin, Geng Yong-Jian, Yu Xi-Yong, Li Yangxin
Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, 215123, People's Republic of China.
Department of Cardiovascular Surgery, Institute for Cardiovascular Science, Soochow University, Suzhou, China.
Adv Exp Med Biol. 2017;998:187-206. doi: 10.1007/978-981-10-4397-0_13.
Cardiovascular diseases resulting from ischemic heart diseases remain to be the main causes of heart failure and death despite significant advances in medical treatment. The development of new therapies for heart failure is thus required to improve the outcome in these patients, and this has led to the development of cell-based therapies. Animal studies showed interesting results using various cell types. Some stem cell based therapies have been tested in clinical trials. Although the results were encouraging, challenges remain. Tumorigenic potential, immune rejection, and low engraftment and survival rate of transplant cells have hindered the widespread application of stem cells in the clinic. Fortunately, exosome based therapy could avoid these problems associated with cell therapy. Future research should focus on how various molecules are sorted into exosomes and this information will help to design better exosomes for treatment of cardiovascular diseases. Recent studies suggest that exosome content can vary depending on how cells are challenged. It would be important to find out exactly what types of cellular stress is needed for producing most useful exosomes. Alternatively, specific molecules can be introduced into exosomes by genetic engineering in order to treat specific conditions and to improve efficacy.
尽管在医学治疗方面取得了重大进展,但缺血性心脏病导致的心血管疾病仍然是心力衰竭和死亡的主要原因。因此,需要开发新的心力衰竭治疗方法来改善这些患者的预后,这导致了基于细胞的治疗方法的发展。动物研究使用各种细胞类型显示出有趣的结果。一些基于干细胞的治疗方法已经在临床试验中进行了测试。尽管结果令人鼓舞,但挑战依然存在。移植细胞的致瘤潜力、免疫排斥以及低植入率和存活率阻碍了干细胞在临床上的广泛应用。幸运的是,基于外泌体的治疗可以避免这些与细胞治疗相关的问题。未来的研究应专注于各种分子如何被分选到外泌体中,这些信息将有助于设计更好的外泌体用于治疗心血管疾病。最近的研究表明,外泌体的内容物可能因细胞受到的挑战方式而异。找出产生最有用外泌体所需的具体细胞应激类型将非常重要。或者,可以通过基因工程将特定分子引入外泌体,以治疗特定病症并提高疗效。
Adv Exp Med Biol. 2017
Adv Exp Med Biol. 2017
Adv Exp Med Biol. 2017
J Cardiovasc Transl Res. 2018-3-10
J Cardiovasc Transl Res. 2019-2
J Cardiovasc Transl Res. 2020-4-24
Adv Exp Med Biol. 2017
Mol Ther Nucleic Acids. 2020-10-4
Front Oncol. 2020-10-23
Biomed Res Int. 2020
Am J Physiol Heart Circ Physiol. 2019-6-7